Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies

BACKGROUND: Risankizumab is a humanized IgG monoclonal antibody that selectively inhibits interleukin‐23 through binding the p19 subunit. In Phase 3 trials, risankizumab demonstrated superior efficacy compared with adalimumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Strober, B., Menter, A., Leonardi, C., Gordon, K., Lambert, J., Puig, L., Photowala, H., Longcore, M., Zhan, T., Foley, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818271/
https://www.ncbi.nlm.nih.gov/pubmed/32320088
http://dx.doi.org/10.1111/jdv.16521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818271/
https://www.ncbi.nlm.nih.gov/pubmed/32320088
http://dx.doi.org/10.1111/jdv.16521

Ejemplares similares